急性髓细胞白血病与CD25表达的相关性探讨

Expression of CD25 in acute myeloid leukemia and it's relationship

目的探讨CD25与急性髓细胞白血病(acute myeloid leukemia,AML)的常见免疫表型标记间的相关性,及CD25与FLT3-ITD基因的关系。方法通过流式细胞术检测CD7、CD117、CD33、CD34、CD38、cyMPO、CD13、CD36、CD56、CD11b、CD19、CD16、CD14、CD64及白介素2三条受体链CD25(α链)、CD122(β链)、CD132(γ链)在36例AML患者骨髓表达,运用PCR技术检测本组患者FLT3-ITD基因的表达。结果 36例AML患者中,CD25+表达率为13.89%(5/36),在AML-M2组为12.5%(1/8)、AML-M4组为18.18%(2/11)、AML-M5组为20%(2/10),CD25+表达率在各组间差别无统计学意义(P>0.05)。表达CD7、CD117、CD33、CD34、CD38、cyMPO、CD13、CD36、CD56、CD11b、CD19、CD16、CD14、CD64、CD122、CD132单克隆抗体的骨髓原始细胞百分比在CD25+AML-M2组和CD25-AML-M2组间、CD25+AML-M4组和CD25-AML-M4组间、CD25+AML-M5组和CD25-AML-M5组间无统计学差异(P>0.05)。PCR结果显示,7例AML患者出现FLT3-ITD突变基因,5例CD25+AML患者组中FLT3-ITD+者为3例,CD25+AML合并FLT3-ITD+率为60%,高于CD25-AML组(P<0.05)。结论 (1)CD25在AML患者中可出现阳性表达,但阳性率较低,CD25与AML患者的FAB亚型和常见的髓系免疫表型标记无明显相关性;(2)CD25+AML患者合并FLT3-ITD基因突变率较高,明确CD25与FLT3-ITD基因的相关性有一定临床意义。

Objective To investigate the relevance between CD25 and common markers of immune phenotype in acute myeloid leukemia （AML）, and the relationship between CD25 and FLT3-ITD gene. Methods The expression of mono-clonal antibodies, including, CD7, CD117, CD33, CD34, CD38, cyMPO, CD13, CD36, CD56, CD11b, CD19, CD16, CD14, CD64 and interleukin-2 three receptor chain CD25 （αchain）, CD122 （β chain）, CD132 （γ chain） were detected by immunofluorescence flow cytometry in 36 cases of AML bone marrow blast. The expression of every group of pa-tients with FLT3-ITD gene were detected by PCR. Results In 36 cases of AML patients, the rate of CD25＋was 13.89%（5/36）, 12.5% （1/8） in AML-M2 group, 18.18% （2/11） in AML-M4 group, 20% （2/10） in AML-M5 group, respectively, and expression rate of CD25＋had been no statistically differences between those subgroups （P〉 0.05）. The percentage of bone marrow blasts which express CD7, CD117, CD33, CD34, CD38, cyMPO, CD13, CD36, CD56, CD11b, CD19, CD16, CD14, CD64, CD122, CD132 monoclonal antibodies has no significant difference between CD25＋AML-M2 group and CD25-AML-M2 group, CD25＋AML-M4 group and CD25-AML-M4 group, CD25＋AML-M5 group and CD25-AML-M5 group, respectively （P〉 0.05）. Seven cases of AML patients with FLT3-ITD mutation, in five cases of CD25＋AML pa-tients three case accompany FLT3-ITD＋ mutation, the rates of FLT3-ITD＋in CD25＋AML was 60%, and higher than CD25-AML group （P 〈0.05）. Conclusion （1）The expression rate of CD25 in AML patients is lower, and no significant correlation in patients in different AML FAB subtypes and common myeloid phenotype markers. （2）Since the FLT3-ITD mutation rates are higher in CD25＋AML patients, there is important significance to clear the correlation between CD25 and FLT3-ITD gene.